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The performance in pediatric human immunodeficiency virus type 1 (HIV-1) infection of
a signal-amplification boosted ELISA for HIV-1 p24 antigen in plasma after heat-mediated
immune complex dissociation was prospectively compared with polymerase chain reac-
tion–based procedures. Diagnostic sensitivity and specificity of the p24 antigen test were 100%
and 99.2%, respectively. Quantification revealed RNA in 85.7% and p24 antigen in 87.4% of
230 samples from 25 infected children. Concentrations of these indices in individual samples
correlated ( ). Introduction or modification of antiretroviral treatment showed con-P ! .0001
cordant responses of RNA and p24 antigen in 39 (90.7%) of 43 instances. The treatment-
induced changes in concentrations of RNA were higher than those of p24 antigen in 11
instances. In 1 instance, however, the concentration change of p24 antigen was greater than
that of RNA ( ). Variation of RNA concentrations was more marked than that ofP = .002
p24 antigen ( ). The p24 antigen test was equivalent to PCR for diagnosing and mon-P = .002
itoring pediatric HIV-1 infection.
The quantity of human immunodeficiency virus (HIV) type
1 components in the plasma mirrors the replication of the virus
in lymphoid tissue [1]. Longitudinal observations of plasma
HIV RNA have revealed that the levels correlate with pro-
gression of HIV-1 infection [2–4]. In consequence, quantifica-
tion of HIV-1 components in plasma has become instrumental
in monitoring HIV-1–infected subjects and their response to
antiretroviral treatment (ART) [5, 6].
Several methods are being employed for quantification of
HIV-1 in plasma, including molecular amplification techniques
of HIV-1 RNA or DNA [7, 8] and detection of HIV-1 p24
antigen by ELISA [9]. Amplification of HIV-1 RNA or DNA
is hampered by the need for costly technical equipment and
expensive reagents and is therefore hardly affordable where
financial resources for health care are limited. By contrast, de-
termination of HIV-1 p24 antigen can be accomplished by using
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simple equipment and at considerably lower costs. Thus, this
latter test, if sufficiently accurate and precise, could provide a
monitoring tool for a more widespread use.
We present here the results of prospectively determined
plasma HIV-1 loads in HIV-1–exposed uninfected and infected
children comparing detection of HIV-1 RNA copy numbers
with detection of HIV-1 p24 antigen levels. This study shows
that the antigen test performs with a high diagnostic sensitivity
and specificity and that quantification of HIV-1 expression by
p24 antigen measurement is as precise as by commercial quan-
titative polymerase chain reaction (PCR) for HIV-1 RNA.
Materials and Methods
Patients and study design. For determination of the diagnostic
sensitivity and specificity, all results of routine HIV-1 testing gen-
erated between 1 January 1994 and 31 December 1997 at the Swiss
National Center for Retroviruses on samples from neonates, in-
fants, or older children born to HIV-1–positive mothers were eval-
uated. Most children were enrolled in the Swiss Neonatal HIV
Study Cohort [10]. Until December 1994, diagnostic testing was
scheduled for age 3 months and thereafter at intervals of 3–6
months up to age 24 months. From January 1995 onward, diag-
nostic testing was scheduled for ages 3–7 days, 2 months, and 6
months. The evaluated cohort included 232 blood samples from
61 children with confirmed HIV-1 infection and 643 blood samples
from 246 infants considered uninfected. A child was considered
infected if a first sample was positive for HIV-1 DNA, RNA, or
p24 antigen and if the subsequent sample was positive for at least
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Table 1. Diagnostic sensitivity of human immunodeficiency virus type
1 (HIV-1) detection methods.
Age
Antigen
neutralized
In-house PCR
viral DNA
In-house PCR
viral RNA
HIV-1 monitor
viral RNA
<10 days 6/12 (50)a 5/12 (42) 3/7 (43) Not doneb
11 days–3 mo. 10/10 (100) 8/8 (100) 7/7 (100) 6/6 (100)
13–6 mo. 19/19 (100) 12/12 (100) 12/12 (100) 9/9 (100)
16 mo. 191/191 (100) 66/66 (100) 26/26 (100) 120/120 (100)
110 days 220/220 (100) 86/86 (100) 45/45 (100) 135/135 (100)
NOTE. PCR, polymerase chain reaction.
a No. samples positive/no. tested (%).
b The sample that was positive in the antigen assay but negative by in-house
PCR for viral DNA. Respective RNA was also negative by the ultrasensitive
HIV-1 monitor version 1.5.
HIV-1 DNA or RNA. All infants who did not meet these criteria
were considered uninfected, provided that they had tested negative
at least twice for DNA or RNA when age 12 months and/or had
seroreverted. The infection status of all infants born toward the
end of 1997 was verified by further testing during the first 6 months
of 1998, resulting in a clear distinction of infected and uninfected
children, with no cases remaining indeterminate. The diagnostically
relevant age distribution of the children is shown in table 1.
For the prospective evaluation of plasma HIV-1 load levels, 25
HIV-1–infected children followed between June 1996 and Decem-
ber 1997 at the HIV outpatient clinic of the University Children’s
Hospital of Zurich were enrolled after informed consent. The age
of the patients at entry was 0.4–15.5 years (mean 7.9; median 9.3),
and stages according to the Centers for Diseases Control classifi-
cation [11] were A2 ( ), A3 ( ), B1 ( ), B2 ( ), B3n = 2 n = 3 n = 3 n = 4
( ), C2 ( ), and C3 ( ). Most patients were partici-n = 4 n = 2 n = 7
pating in clinical trials of the Pediatric European Network for
Treatment of AIDS or of the Pediatric AIDS Group of Switzerland.
Blood samples were collected at time points dictated by the trial
protocols, before change of treatment, or at regular 3-month
intervals.
Circadian variation of plasma HIV-1 levels was studied in 5
patients after informed consent and in no relation to immuno-
globulin infusions. Two children (figure 1; patients 2 and 4) were
receiving zidovudine and didanosine and 1 child (figure 1; patient
1) zidovudine and zalcitabine, whereas 2 children (figure 1; patients
3 and 5) were without antiretroviral treatment. Blood specimens
were drawn from implanted intravascular catheters (used for
monthly immunoglobulin infusions) into vacutainer CPT tubes
(Becton Dickinson, Basel, Switzerland) at 4 defined time points (at
hours 7, 9, 12, and 16) on each of 2 different days. At each time
point, the first 5 mL of aspirated blood were discarded, to avoid
dilution bias. Plasma was harvested within 30 min and frozen at
2707C until retrospective batch testing was performed.
Tests for viral DNA or RNA. For diagnostic purposes, 1-mg ali-
quots of DNA extracted from peripheral blood mononuclear cells
were prospectively tested by an in-house PCR method for HIV-1
in gag and long terminal repeat sequences, as described elsewhere
[12]. All tests were done in duplicate reactions for both target
regions. A positive result of DNA PCR required reactivity for both
target regions, with duplicate reactivity in at least 1 of them. Qual-
itative PCR for viral RNA in plasma was performed in some sam-
ples that had already been tested for viral DNA. An in-house
method based on detection of the same sequences as for DNA PCR
was used [13]. A positive result of RNA PCR also required reac-
tivity for both target regions, but each region was assessed with
only a single reaction. In both methods, DNA and RNA PCR, a
single DNA or cDNA copy, respectively, can be detected [9].
For real-time prospective quantification of HIV-1 RNA in
plasma, an in-house procedure was not available; the Amplicor
HIV monitor version 1.0 kit (Roche Molecular Systems, Basel,
Switzerland), with a nominal lower quantification limit of 400 cop-
ies/mL, was therefore used for testing according to the manufac-
turer’s guidelines. From August to December 1997, the Amplicor
HIV-1 monitor kit was used in combination with Roche’s mix-in
primers to improve detection of HIV-1 subtypes A and E. No
increases of RNA unparalleled by increases in p24 antigen were
seen after the introduction of mix-in primers. This indicated that
subtypes A, E, or G (which were not well detected without the
mix-in primers) were not present in the studied cohort and that,
consequently, sequential data from samples prior to and subsequent
to this modification could be merged for each child.
Viral antigen. Detection of p24 antigen in heat-denatured plasma
was done prospectively (real time) and essentially as described else-
where [9]. Briefly, 100 mL plasma was diluted with 500 mL of 0.5%
Triton X-100 in 1.5-mL Eppendorf tubes, denatured by heating at
1007C for 5 min on a Techne (Cambridge, UK) dry heat block,
and tested in duplicate with the NEN/DuPont HIV-1 core profile
ELISA in combination with the ELAST ELISA amplification sys-
tem (both purchased from NEN Life Science Products, Geneva).
The cutoff level for positivity in diagnostic testing was determined
for each assay plate by calculating the mean absorbance of 8 HIV-
1–negative controls run on the same plate plus 5 SD. For quan-
tification, a cutoff corresponding to the mean plus 3 SD was used.
Absorbance was read by using a Dynatech MR5000 ELISA reader
(Microtech Produkte, Embrach, Switzerland). Antigen was quan-
tified with a kinetic analysis by using the Quanti-Kin detection
system (Tib Molbiol Srl, Genova, Italy). This permitted quantifi-
cation in a range ∼500–6,250,000 fg/mL with a single sample di-
lution [14].
All reactive samples from children in whom infection with HIV-
1 as defined above had not, or not yet, been firmly established were
subjected to confirmatory antigen neutralization, by use of heat-
denatured plasma and NEN/Du Pont’s confirmatory reagents and
procedure.
Data analysis. Analysis of data, figure plotting, and statistics was
done employing the StatView 4.02 program for Macintosh (Abacus
Concepts, Berkeley, CA). Values below the limit of detection were
set arbitrarily to 100 copies/mL for RNA and 100 fg/mL for p24
antigen, respectively, both in the calculations and in the figures.
For each patient, corresponding levels of HIV-1 RNA and p24
antigen were compared for their respective changes and longitu-
dinal evolution in relation to unmodified or modified ART. Re-
actions of HIV-1 plasma levels determined by the 2 methods were
regarded as concordant when both methods showed increase or
decrease of HIV-1 plasma levels by10.5 log10 and when both meth-
ods showed HIV-1 plasma levels remaining within a range of 50.5
log10, respectively. The change in HIV-1 plasma levels was regarded
as similar in both methods when the changes in concentration did
not differ by 10.5 log10. If the response of HIV-1 plasma levels
determined by 1 method became apparent only in blood specimens
after the specimen showing a response by the other method, the
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Table 2. Diagnostic specificity of p24 antigen in uninfected chil-
dren of mothers positive for human immunodeficiency virus.
Age No. children
Antigen
initially reactive,
no. (%)
Antigen
neutralized positive,
no. (%)
<10 days 148 15 (10.1) 2 (1.4)
110 days–3 mo. 116 6 (5.2) 2 (1.7)a
13–6 mo. 68 4 (5.9) 0
16–12 mo. 106 3 (2.8) 0
112 mo. 205 12 (5.9) 1 (0.5)b
All ages 643 40 (6.2) 5 (.8)
a Two samples of same infant: 27 pg at 0.5 months, 100% neutralization;
2 pg at 3 months, 72% neutralization.
b Child was positive for p24-specific IgA antibody at birth (transplacental
transfusion).
Figure 1. Precision of p24 antigen and human immunodeficiency virus type 1 (HIV-1) RNA quantification in circadian variation of HIV-1
load in 5 children.
response of HIV-1 plasma levels determined by the first method
was regarded as delayed. Finally, longitudinal variation of HIV-1
plasma levels by 10.5 log10 while ART was not modified was judged
to be increased variation.
Results
Diagnostic sensitivity and specificity. Diagnostic sensitivity of
p24 antigen– and PCR-based tests was determined in a total
of 232 samples derived from 61 HIV-1–infected children at dif-
ferent ages with no ART (table 1). Because of limited sample
volumes in neonates and infants and the high cost of PCR
testing, not all samples were tested by all 4 tests, but all were
at least tested for p24 antigen. Above the age of 10 days, all
tests were positive in all samples tested. Below 10 days, the
antigen test was neutralization positive in 6 of 12 samples. DNA
PCR, as well as the in-house PCR for viral RNA, missed 1 of
the samples positive by antigen assay. This sample was also
negative by the ultrasensitive HIV-1 monitor version 1.5. All
positive RNA results were confirmed by a positive result in the
subsequent sample.
Determination of diagnostic specificity of the p24 antigen
assay was based on testing a total of 643 plasma samples from
246 infants or children born to HIV-1–positive mothers con-
sidered uninfected (table 2). Although reactivity in initial testing
was relatively high, specificity after neutralization was 99.2%.
Two of the positive results were from an infant who exhibited
27 pg/mL of 100% neutralizable antigen at 0.5 months and a
decreased amount of 2 pg/mL (72% neutralizable) at 3 months,
whereas PCR for viral DNA or RNA were negative in both
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Figure 2. Correlation of p24 antigen and human immunodeficiency
virus type 1 (HIV-1) RNA concentrations in 230 plasma samples from
25 HIV-1–infected children.
samples. In a subsequent sample taken at 5.6 months, antigen
was also undetectable. A test for particle-associated reverse
transcriptase activity, which permits detection of HIV as sen-
sitively as PCR for viral RNA but is independent of genomic
sequence variation [15], was negative. Despite confirmed evi-
dence of transient antigenemia, this child is thus considered
uninfected. One positive sample was from an uninfected child
with p24-specific IgA antibody at birth [16]. The 2 other positive
samples were from the neonatal period, during which p24 an-
tigen of maternal origin may be transiently detectable. Among
570 samples tested for viral DNA, there were no false-positive
results. Three samples (0.53%) had an indeterminate result (1
of 4 reactions positive) but were negative by the in-house
method for viral RNA, and in 2 instances there was no valid
result because of a technical failure. Two (1.4%) of 141 samples
tested with the in-house method for viral RNA gave false-
positive findings, resulting in a diagnostic specificity of 98.6%,
and 2 more showed an indeterminate result. Only 5 of the 643
samples from uninfected children that were tested for antigen
were tested for RNA with the HIV-1 monitor, and all were
negative.
Diurnal variation of plasma HIV-1 load. Variation of plasma
HIV-1 load at different time points of the day was studied in
5 HIV-1-infected children. The results of HIV-1 quantification
in blood specimens drawn at 4 defined time points on each of
2 different days are presented in figure 1. The SD for the 8
samples of a single patient ranged from 0.07 to 0.15 log10 by
use of HIV-1 RNA quantification and from 0.02 to 0.11 log10
by use of p24 antigen quantification.
Correlation of p24 antigen and HIV-1 RNA copy numbers.
Comparison of real-time HIV-1 RNA and p24 antigen quan-
tification in 230 blood samples from the 25 HIV-1–infected
children showed detection of HIV-1 RNA in 197 (85.7%) chil-
dren and of p24 antigen in 201 (87.4%). Twenty (8.7%) samples
negative for HIV-1 RNA were found to be positive for p24
antigen and 16 (7.0%) samples negative for p24 antigen were
positive for HIV-1 RNA. Thirteen (5.7%) samples were negative
in both tests. The correlation of both tests by Spearman rank
correlation and analysis of variance was ( ;2R = .658 R = .419
) when values below cutoff were included in the analysisP ! .001
and ( ; ) when values below cutoff2R = .560 R = .296 P ! .0001
were excluded (figure 2). Although the 2 assays measure dif-
ferent HIV-1 products in different units, a surprisingly good
correlation was found, as shown in figure 2.
Influence of antiretroviral treatment on HIV-1 load parame-
ters. On enrollment into the study, 7 patients were naive for
ART, 15 were receiving nucleoside reverse transcriptase inhib-
itors (NRTIs), and 3 were being treated with NRTIs plus a
protease inhibitor (PI). During the study period, ART was in-
troduced or modified (addition or discontinuation of drug) in
24 patients on 43 occasions. In 13 (30.2%) of these events, an
introduction or modification of ART involved only NRTIs (fig-
ure 3B, 3C, 3D, 3E), in 17 (39.5%) only PIs (figure 3E), and
in 13 (30.2%) NRTIs plus PIs (figure 3A, 3D, 3F). The mean
numbers of viral load determinations after these events (until
the next event or conclusion of the study) were 2.5 (range, 1–5),
3.2 (1–7), and 3.2 (1–7), respectively. The first assessment of
viral load after introduction or modification of ART showed
overall concordant responses of RNA and p24 antigen in 39
(90.7%) events: 13 of 13 for NRTIs plus PIs (figure 3A, 3D,
3F), 15 (88.2%) of 17 for PIs only (figure 3E), and 11 (84.6%)
of 13 for NRTIs only (figure 3B, 3C, 3D, 3E). The treatment-
induced changes in concentrations were more pronounced for
HIV-1 RNA in 11 (25.6%) instances and for p24 antigen in 1
(2.3%) instance ( , Fisher’s exact test, 2-tailed). For ex-P = .002
ample, in figure 3C, after the addition of ritonavir at month
140, the viral RNA dropped by 2 log10 within half a month,
whereas the reduction in p24 antigen was minimal (from 5 to
4.75 log10). Variation of HIV-1 load, as judged by the 24 treat-
ment modifications that were assessed by 12 follow-up mea-
surements, was more marked for HIV-1 RNA than for p24
antigen in 14 (58.3%) instances, whereas variation was more
marked for p24 antigen than for RNA in only 3 (12.5%) in-
stances ( , Fisher’s exact test, 2-tailed). In figure 3B, forP = .002
example, the addition of ritonavir induced an only modest but
sustained decrease in p24 antigen, whereas RNA quickly
dropped from an initial level of almost 5 log to undetectable
but bounced as quickly back to 4 log. The net decrease in both
markers is thus similar. Interestingly, the sustained increase of
CD4 during this period correlated better with that of antigen
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Figure 3. Longitudinal courses of human immunodeficiency virus type 1 (HIV-1) load markers and CD41 lymphocytes and effects of anti-
retroviral treatment in 6 representative children. d4T, stavudine; ddI, dideoxyinosine; ddC, dideoxycytidine; 3TC, lamivudine; NFV, nelfinavir;
RTV, ritonavir; ZDV, zidovudine; n.d., not detectable. For further details, see text.
than RNA, and a similar observation could be made in the
course represented in figure 3F.
Discussion
This is the first prospective study that compares HIV-1 DNA
or RNA and p24 antigen with regard to their performance as
a diagnostic test for pediatric HIV-1 infection and as tools for
quantification of virus in chronically infected infants. The di-
agnostic sensitivity of signal-amplification boosted HIV-1 p24
antigen ELISA after heat-mediated immune complex dissoci-
ation was found to be as high as that of PCR detection of viral
DNA or RNA in both untreated (table 1) and treated children
(figure 2). The high degree of specificity afforded by a conse-
quent use of confirmatory antigen neutralization permits one,
as with PCR, to clearly establish the status of HIV-1 infection
in the first few weeks or months after birth. As a matter of
fact, during the neonatal period, the p24 antigen was correctly
positive with a sample that was still negative by PCR methods
capable of detecting a single HIV-1 copy in 1 mg of leukocyte
DNA or, respectively, about 50 HIV-1 RNA copies/mL of
plasma. No sample from an untreated infected child seen in
our laboratory during the 4-year study period was positive by
PCR but negative by antigen testing. Seventy percent of the
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uninfected children tested at age <6 months had perinatal zi-
dovudine prophylaxis. Among them, there was 1 child who
showed positive RNA but negative antigen and DNA PCR at
age 2 months, whereas results at 1 week and 4 months were
all negative. Regarding the prospective diagnostic specificity,
the 99.2% of the antigen test after neutralization compared well
with the in-house method for viral RNA (98.6%) and was al-
most as good as the method for viral DNA (no false positives).
A direct comparison of specificity with the commercial HIV-1
monitor kit could not be performed in this study, but the recent
literature shows that this method, when used diagnostically,
may apparently also yield false-positive results [17]. Thus, the
p24 antigen test can be used as a screening tool, followed by
neutralization tests or, if available, PCR in reactive samples.
In contrast, the antigen test may also be used diagnostically
for the confirmation of positive PCR results. Used in combi-
nation, these 2 tests should provide an optimum of diagnostic
safety. Quantification of p24 antigen proved to be as precise
and sensitive as quantification of HIV-1 RNA by a commercial
PCR kit with a nominal detection limit of 400 copies/mL (figure
2). Levels of p24 antigen in individual patients were correlated
and longitudinally concordant with levels of HIV-1 RNA in
individual patients but showed less variation than the latter
(figure 3).
The precision of p24 antigen quantification was shown by a
study of plasma HIV-1 loads at 4 time points each on 2 different
days (figure 1). The range of diurnal variation of p24 antigen
levels was similar to the range of variation seen when deter-
mining HIV-1 load by measuring RNA copy numbers (0.108
vs. 0.057 log10). Kinetics of HIV-1 RNA concentrations in pe-
diatric patients have been determined in an earlier study show-
ing variations in a similar log10 range [18]. Notably, in our study,
diurnal variation of HIV-1 load, as determined by both meth-
ods, was not significantly affected by the time of intake of
antiretroviral drugs. This is a substantial observation for prac-
tical reasons, in that for each individual patient blood speci-
mens need not be drawn at specified time points related to drug
intake to allow for comparison of longitudinally determined
values.
One significant finding of this study is the good correlation
of p24 antigen levels and of HIV-1 RNA copy numbers (figure
2; ) in children, regardless of whether they were re-P ! .0001
ceiving ART. In an earlier study, we clearly showed that the
use of p24 antigen detection after heat-mediated immune com-
plex dissociation provides a sensitive means for early diagnosis
of infection in HIV-1–exposed infants [12]. Similar results were
obtained by employing the more widely used acid-dissociated
p24 antigen test [19–22]. The sensitivity of antigen detection in
the present study was even higher because of the addition of
a signal-amplification step to the ELISA, by which the detection
limit was lowered to about 0.5 pg/mL. Three samples that were
negative in our earlier work [12] now tested positive (data not
shown). The excellent diagnostic performance of the amplifi-
cation-boosted p24 antigen assay in vertically HIV-1–exposed
children has also been reported by others who used our pro-
cedure in a study of African children [23]. Recently, our group
showed that heat-mediated immune complex dissociation fol-
lowed by this signal-amplification boosted ELISA detects p24
antigen in plasma of HIV-1–infected adults with the same sen-
sitivity as does PCR [24]. In a subsequent retrospective analysis
conducted in HIV-infected adults, this p24 antigen detection
procedure proved to perform comparably to RNA PCR in
monitoring the efficacy of ART [9].
An important fact regarding patient monitoring is that, on
introduction or modification of ART, the vast majority of re-
sponses in the p24 antigen load were concordant with the HIV-
1 RNA load responses. Although the reduction of HIV-1 RNA
could be more pronounced and prompt than the reduction of
p24 antigen levels, the opposite was also observed. However,
p24 antigen levels showed significantly less variation than HIV-
1 RNA. This might be caused by p24 antigen’s being more
refractory than RNA to intercurrent events, resulting in pro-
virus activation—for example, immunizations or intercurrent
illnesses—but chart review disclosed no such events (data not
shown). Thus, longitudinal quantification of p24 antigen after
introduction of highly active ART including PIs provides cli-
nicians with information of sufficient accuracy and of less con-
fusing variability than quantification of HIV-1 RNA. This is
of clinical impact because the recommendations for modifica-
tion of ART on the basis of changes of plasma HIV-1 load and
the frequency of plasma HIV-1 load assessment after such mod-
ification are not yet clear.
In conclusion, quantification of plasma HIV-1 load by signal-
amplification boosted ELISA detection of p24 antigen after
heat-mediated immune complex dissociation offers a highly
precise alternative to RNA PCR for monitoring HIV-1 disease
evolution and its response to ART. The considerably less ex-
pensive p24 antigen detection (in Switzerland 35 Swiss francs
[∼$23 US]/test are charged for screening and 50 Swiss francs
for a neutralization or a quantification test) render this tool
affordable to a larger community of patients than does RNA
PCR (200 Swiss francs/test for a qualitative and 275 Swiss
francs for a quantitative test).
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